Compare VALN & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | USNA |
|---|---|---|
| Founded | 2012 | 1992 |
| Country | France | United States |
| Employees | N/A | 1570 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.5M | 397.1M |
| IPO Year | 2021 | 1996 |
| Metric | VALN | USNA |
|---|---|---|
| Price | $5.26 | $22.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | 18.7K | ★ 108.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $1,060,902,000.00 |
| Revenue This Year | N/A | $3.90 |
| Revenue Next Year | $93.87 | $6.21 |
| P/E Ratio | ★ N/A | $53.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.04 | $16.60 |
| 52 Week High | $12.25 | $38.32 |
| Indicator | VALN | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 72.81 |
| Support Level | $5.10 | $18.71 |
| Resistance Level | $5.49 | $22.71 |
| Average True Range (ATR) | 0.19 | 0.84 |
| MACD | 0.03 | 0.28 |
| Stochastic Oscillator | 48.00 | 100.00 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).